EVOLVING REGULATORY POLICIES FOR ORPHAN DRUGS POST-COVID-19: UK AND INDIAN PERSPECTIVES
Background: Globally, rare diseases affect around 300 million people, but most of these disorders lack approved treatments. Orphan drugs - pharmaceuticals for rare diseases - represent a special category of drugs, balancing the profit disincentive with the compelling need. The COVID-19 pandemic (2019-2023) has ushered...